Other monoclonal antibody therapies such as rituximab, which have shown similar anti-cancer immune responses in preclinical models, function by upregulating type I IFNs, which leads to maturation of DCs to bolster CD8+ T-cell effector functions [72]. Here, CD8A is linked to cancer.